Swarna Khare
Director - Global Integrated Evidence Planning Novartis AG
Swarna Khare is a seasoned RWE and evidence strategy leader with over 14 years of experience translating rigorous statistical and analytical expertise into impactful real-world evidence that accelerates drug launches and commercialization. Originally trained as a statistician, she is passionate about leveraging the rapidly expanding ecosystem of real-world data to transform patient outcomes and support smarter decision-making across the product lifecycle. Swarna is a vocal advocate for clear, accessible communication of the value of RWE, ensuring patients understand and benefit from the data they help create, and is deeply motivated by innovation that pushes the boundaries of what is possible in healthcare.
Seminars
This interactive discussion will explore how to ensure Integrated Evidence Plans convert into tangible decision-making influence across development and commercialization. Join peers to share practical approaches for accelerating evidence delivery, securing internal stakeholder buy-in, and demonstrating clear business impact, from reducing protocol amendments to improving market access readiness.
Join this roundtable to discuss:
• How do we ensure IEPs actually influence development decisions vs. sitting on a shelf?
• What governance structures enable rapid change when evidence needs shift?
• How can RWE teams demonstrate impact in real time (not just post-launch)?
• Where have teams successfully avoided expensive amendments using early RWE?
- Understanding how to overcome role confusion and shifting responsibilities in cross-functional RWE projects by embedding robust IEP governance
- Exploring frameworks to balance standardisation and agility, ensuring continuity despite team turnover or organisational change
- Gaining strategies to prioritise projects effectively, align evidence generation with stakeholder needs, and prevent duplication of efforts across functions
- Incorporating AI in the development of integrated evidence plans – what are the pros and cons and how can we move forward?
